BioAI Health develops multimodal causal AI technology to map disease biology, identify digital biomarkers, and discover novel drug targets for precision medicine. Their platform accelerates biomarker screening from weeks to hours by analyzing complex data, including spatial transcriptomics and histopathology images. The company offers AI biomarker services and data sourcing to advance clinical R&D and optimize patient matching to therapies.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for identifying genetic mutations and drug targets in cancer are inefficient, hindering effective disease diagnosis and personalized therapy selection for patients. This challenge stems from the complexity of cancer biology and the difficulty in translating research findings into clinical applications.
Solution
BioAI Health leverages multimodal AI and in-silico phenotype projection to enhance precision medicine in oncology. The company's PredictX-Platform maps the causal biology of disease, develops digital biomarkers, and identifies novel drug targets. By analyzing multimodal data, including spatial transcriptomics and computational pathology on tissue slides, BioAI optimizes clinical research and drug development processes, ultimately improving patient outcomes.
Target Audience
BioAI Health primarily serves biopharmaceutical companies and clinical research organizations seeking to accelerate drug discovery and development, as well as clinical laboratories and IVD manufacturers.
Features
- PredictX-Platform featuring multimodal causal AI and in-silico phenotype projection
- AI biomarker services for identifying genetic mutations within histopathology images
- AI drug discovery services for identifying drug targets for driver genes of cancer
- Multimodal data analysis including spatial transcriptomics
- Computational pathology on H&E-, IHC- and FISH-stained tissue slides
- Data sourcing services from BioAI’s clinical data network
- Biomedical guidance from board-certified pathologists and translational scientists
- Optimization and validation of AI models
- Productization and deployment of digital tests